There is a dearth of research examining the associations between cognitive function and quality of life (QoL) in patients with head and neck cancer (HNC), despite much research examining QoL and some research examining cognitive function in this population.
C hanges in cognition are common with normative aging. However, cognitive impairment represents a range in cognition from more substantial than normative changes and up to the manifestations of dementia. 1 The prevalence of cognitive impairment in excess of normative changes due to aging is estimated at 16% to 22% of the population. 1 As would be expected, the risks of cognitive impairment increase with age, with those older than 65 years having an incidence of 14 to 111 per 1000 patient-years. 2, 3 Cognitive impairment is also associated with sex (ie, more common in men), 4 lower level of education attainment, tobacco use, and heavy alcohol use. 5 There also exists a bidirectional relationship between psychiatric factors and cognitive impairment, with premorbid recurrent depression being an identified contributing factor to cognitive impairment and those with cognitive impairment having a higher risk of developing depression. [6] [7] [8] Anxiety has also been associated with higher risk of cognitive impairment. 3, 5 Previous research has found that cognitive impairment was associated with substance abuse, psychiatric symptoms, and quality of life (QoL) in other medical disorders, including neurological disorders [9] [10] [11] and cancers. 12, 13 Cognitive impairment has also been associated with important treatment variables such as treatment adherence for rehabilitation and outcomes in patients with cancer. 14 In particular, cognitive impairment at cancer treatment initiation was associated with a 6 times higher risk of death in patients with breast, prostate, or colorectal cancers. 15 Additionally, both cognitive impairment and poorer QoL have separately been associated with decreased overall survival in patients with cancer. [12] [13] [14] While there exists significant previous research examining QoL in patients with head and neck cancers (HNCs) and some examining cognitive function in patients with HNC, there is a dearth of research examining the associations between QoL and cognitive function in this population. Head and neck cancer represents 3% of all malignant neoplasms in the United States. 1 Head and neck cancer typically presents in an older population and is more common in men and in those with tobacco and/or alcohol use [15] [16] [17] [18] -all of which are also risk factors for cognitive impairment. [2] [3] [4] [5] Previous research has determined that patient-reported cognitive functioning prior to HNC treatment is independently associated with disease progression and survival. 19 Additionally, in research examining cognitive function prior to induction chemotherapy or chemoradiation treatment for HNC, up to 47% of patients demonstrated cognitive impairment on neuropsychological tests. 20 However, these studies often rely on long neuropsychological test batteries or patient self-report. Whereas previous cross-sectional and longitudinal research has examined patient self-reported cognitive impairment and QoL in patients with HNC, these 2 variables have not been examined in relation to one another. [20] [21] [22] [23] To address the dearth of research examining the associations between QoL and cognitive function in patients with HNC, the present study sought to better elucidate the associations between cognitive functioning and QoL in patients prior to treatment for head and neck cancer within a multidisciplinary care team. We also worked to identify patient and clinical correlates associated with both cognitive function and QoL.
Methods
Approval with waiver of consent was obtained from the Henry Ford Health System Institutional Review Board for a retrospective medical record review of patient variables and selected outcomes. All patients with a diagnosis of oral cavity, oropharynx, hypopharynx, or larynx HNC between August 2015 and December 2016, regardless of medical and/or neurological comorbidities, who had both a pretreatment semistructured psychosocial interview and cognitive assessment with a clinical health psychologist and completed the Functional Assessment of Cancer Therapy-Head & Neck version 4 (FACT-H&N) during pretreatment assessment with the speech and language pathologist were included in analyses. Further patient demographic information and treatment variables, including clinical staging at initial presentation, treatment recommendations, and adherence to these recommendations were obtained via medical record review. All psychosocial and psychiatric variables were gathered during the evaluation with the health psychologist using a semistructured clinical interview. Psychosocial variables included current and past alcohol use, tobacco use, illicit drug use, and social support. Social support was dichotomized as adequate or inadequate, with adequate support indicating that the patient had perceived emotional and instrumental (eg, transportation, help at home) support available. Psychiatric variables included current and previous psychiatric care and psychotropic medication use, as well as current and baseline psychiatric symptoms. Depression was assessed as a symptom count based on Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition) criteria, and anxiety was assessed as a presence or absence of generalized anxiety symptoms prior to cancer diagnosis. Adherence to treatment recommendations was defined as completing treatment as recommended. Those patients who did not receive the full treatment as recommended by the multidisciplinary tumor board were considered nonadherent, regardless of reason for this nonadherence.
Key Points
Question What are the associations between cognitive functioning and quality of life (QoL) in patients prior to treatment for head and neck cancer within a multidisciplinary care team?
Findings In this case series of 83 adults evaluated before head and neck cancer treatment, 46 (55%) had cognitive impairment. The number of depressive symptoms was associated with impairments in delayed recall and QoL; cognitive impairment and delayed recall were associated with lower QoL; and past substance use was associated with current QoL and cognitive function. 28, 29 In normal controls, the MoCA has demonstrated similar sensitivity and specificity compared with the more commonly used Mini-Mental State Examination (MMSE). However, the MoCA demonstrated improved sensitivity and specificity in both mild cognitive impairment and Alzheimer disease populations compared with the MMSE. [30] [31] [32] The MoCA was chosen for the purposes of this study due to its sensitivity and specificity, as well as its brevity, ease of use, multiple equivalent test forms allowing for repeated testing, availability in vision-and hearing-impaired versions and other languages, paper testing forms, and common use in other medical populations within our institution.
Meaning

Functional Assessment of Cancer TherapyHead and Neck Cancer
The FACT-H&N 33 is a validated measure of QoL in patients with HNC. The FACT-H&N is composed of 38 Likert-scored items, with higher scores indicating better QoL. A total score on the FACT-H&N can be calculated by summing the 5 domain subscales: physical well-being, social well-being, emotional wellbeing, functional well-being, and head and neck-specific well-being. 29 The FACT-H&N is commonly used in research examining QoL in patients with HNC and was chosen in this study for the brevity of the measure, the domain subscales, and the utility in clinical practice.
Analytic Plan
Data were analyzed using SPSS statistical software (IBM Corp). Descriptive statistics were computed for all demographic and cancer variables, substance use, psychiatric symptoms, QoL, and MoCA scores. Student t tests were used for comparison between groups, and bivariate correlations were used for comparison between interval variables.
Results
Demographic Characteristics
Patients were a sample of 83 patients presenting for treatment of HNC to the Department of Otolaryngology-Head and Neck Surgery at an academic medical center in a Midwest urban center. The patients' mean age was 59.54 (95% CI, 57.23-61.73) years. Additional demographic information can be found in Table 1 .
Patients were assessed in the pretreatment clinic prior to initiating treatment following presentation at a multidisciplinary tumor board. Appropriate staging is determined at the tumor board, and in this patient cohort, 60 (72%) patients had a late-stage cancer (American Joint Committee on Cancer stage III-IV). Sixty-three (76%) of patients followed the treatment recommendations made by the tumor board. Additional cancerspecific and treatment variables can be found in Table 1 .
At pretreatment assessment, 25 (30%) patients were using tobacco products and 61 (73%) patients had a history of tobacco use. Heavy alcohol use was common, with 48 (58%) reporting past heavy alcohol use (ie, weekly binge drinking >5 standard drinks or more than recommended moderate alcohol use of 1 standard drink/d for women or 2 standard drinks/d for men) and 23 (28%) reporting current heavy alcohol use ( Table 2) . Additionally, 12 (14%) reported current illicit drug use and 38 (46%) past illicit drug use, with the most common illicit drug being marijuana, followed by cocaine and heroin.
Overall, 46% (n = 38) of patients reported a psychiatric history, with 36% (n = 30) of all patients reporting elevated baseline anxiety. At the time of assessment, patients reported a mean of 2.43 depressive symptoms (range, 0-8) (Table 2) , with 6% (n = 5) of all patients reporting 5 or more depressive symptoms and 6% (n = 5) reporting passive suicidal ideation. Despite only 5% (n = 4) patients reporting current engagement in mental health treatment (ie, being under the care of a psychiatrist and/or engaged in psychotherapy), 21 (25%) patients had a history of taking psychotropic medications and 27 (33%) were currently taking a psychotropic medication, typically prescribed by a nonpsychiatric clinician (Table 2) .
In the present study, reliability of the MoCA was good (Cronbach α = .77). Table 3 presents the MoCA total and subscale descriptives. In the present sample, the mean MoCA score was less than the cut score of 26 out of 30, indicating that most patients would be considered cognitively impaired. In particular, 45% (n = 37) scored in the nonimpaired range (ie, overall MoCA score ≥26). Fifty-five percent (n = 46) of all patients scored in the impaired range, with 54% (n = 45) of all patients scoring between 18 and 25 (ie, level of mild cognitive impairment), and 1% (n = 1) between 10 and 17 (ie, level of Alzheimer disease).
The FACT-H&N reliability was acceptable to good, depending on the scale (overall QoL Cronbach α = .91, physical wellbeing α = .66, social well-being α = .75, emotional well-being α = .67, functional well-being α = .89, head and neck-specific well-being α = .82). Table 3 presents the FACT-H&N total and subscale descriptives.
Cognitive Function and QoL
Patient scores on the language subscale were positively associated with social QoL/well-being. Patient scores on delayed recall were positively associated with overall QoL, emotional QoL/well-being, and functional QoL/well-being. There were no other significant associations between MoCA total or subscales and QoL scales ( Table 4) .
Cognitive Function, QoL, and Demographic and Psychosocial Variables Table 5 highlights the associations between cognitive function, QoL, and demographic variables. In particular, age was negatively associated with executive function, delayed recall, and total MoCA score, indicating that older patients have increasing difficulty with these processes. Age was also negatively associated with head and neck-specific well-being. Patient level of education was positively associated with attention/concentration (r = 0.22; 95% CI, 0.02-0.40) and abstraction (r = 0.23; 95% CI, 0.03-0.42), indicating that those with higher educational attainment demonstrated higher scores in these processes. Table 5 also highlights the associations between cognitive function, QoL, and psychosocial variables. The number of depression symptoms reported by patients was negatively associated with delayed recall scores. Additionally, number of depression symptoms was also negatively associated with the overall QoL and each QoL/well-being subscale. Higher baseline anxiety was associated with lower emotional well-being and impairment in the language subscale. Furthermore, current benzodiazepine use was associated with lower overall, physical, emotional, and functional QoL/ well-being. As would be expected, lack of social support for treatment was associated with lower social well-being (t(81) = −3. Cognitive Function, QoL, and Substance Use 
Discussion
The present study sought to better elucidate the associations between cognitive functioning and QoL in patients prior to treatment for HNC within a multidisciplinary care team. We also worked to identify patient and clinical correlates associated with both cognitive function and QoL. Slightly more than 50% of patients presented with at least mild cognitive impairment at pretreatment assessment. This is in proportion to previous findings of 47% of patients presenting with cognitive impairment prior to treatment. 20 As would be expected, cognitive impairment was related to age and educational attainment. 25 As with previous research in patients with non-HNC disorders, cognitive impairment was associated with QoL in patients with HNC. [9] [10] [11] [12] [13] In particular, language and delayed recall (ie, memory) were associated with poorer QoL in multiple domains. Interestingly, there were no significant relationships between cognitive impairment and QoL in the physical or head and neck-specific domains. This may indicate that impairments in cognitive function have a larger effect in the domains of a patient's life that are important to psychosocial functioning, such as emotional functioning, daily independence, and social support and engagement. It is also likely that these areas may influence the patient's ability to appropriately engage in HNC care. Hence, this is an area for future research. Similar to previous research demonstrating a relationship between psychiatric symptoms, cognitive impairment, and QoL, 3, [6] [7] [8] [9] [10] [11] the present study found these associations, particularly with depressive symptoms and anxiety. The consistency in these associations within the research highlight the importance of clinicians not just identifying pretreatment psychiatric symptoms and monitoring for these symptoms throughout cancer treatment, but also treating these appropriately with referral to behavioral health clinicians and/or psychotropic medications. In contrast to previous research, 23, 34 cognitive impairment in the present study was not related to heavy alcohol use. Previous research has shown heavy alcohol use to be a predictor of cognitive impairment. 34 However, past heavy alcohol use was associated with poorer QoL across most domains. Perhaps most notably, past heavy alcohol use was associated with poorer emotional well-being. This finding may indicate that patients with heavy alcohol use are less likely to have the coping strategies necessary to cope with their cancer diagnosis. This limitation in coping has been found to interfere with engagement in treatment, adherence, and survival in cancer. 12, 23, 35, 36 Adding to the literature in this area, the present study also demonstrated that past tobacco use was associated with QoL.
Limitations
The present study is a case series of patients presenting for treatment of HNC at a tertiary care center that practices multidisciplinary care. Whereas the field of HNC care is moving toward specialty care at tertiary centers, this does not represent a majority of HNC care settings. Hence, there are some limitations to the generalizability of the results that warrant future research. Whereas the MoCA is a brief cognitive assessment, making it clinically useful in determining cognitive function and the need for further neuropsychological workup, it is limited by patient engagement in testing, fatigue, and other psychosocial variables. These limitations are true for most forms of psychological assessment, and these limitations should not deter further investigation of cognitive function in this population, particularly in light of research demonstrating the role of cognitive impairment in treatment adherence. Additionally, medical comorbidities known to affect cognitive function were not assessed in the present study and future research should include comorbidities. Because the present study was cross-sectional, it can only demonstrate associations between variables, not directionality. Future research should focus on prospective, longitudinal studies in patients with HNC to examine QoL, as well as cognitive and mood symptom changes, across treatment and how these may affect disease-free and overall survival.
Conclusions
The dearth of research examining the associations between QoL and cognitive function in HNC highlights the need for research to better elucidate the relationships among cognitive impairment, QoL, and other psychosocial variables within the context of treatment adherence and outcomes. Increased understanding of these factors and their interaction with the ability to rehabilitate, morbidity, and mortality would aid in the development of both medical and psychosocial interventions that influence morbidity and mortality in this population. Such intervention should likely start with identification of risk factors, such as alcohol and tobacco use, in addition to the cognitive impairment itself prior to treatment initiation, thus allowing the treatment team to intervene and possibly improve both patient and treatment outcomes (eg, QoL and survival). Further research is needed in this area, particularly with patients with HNC due to the high prevalence of comorbid substance use and psychiatric symptoms. The present study sought to better elucidate the associations between cognitive functioning and QoL in patients prior to treatment for HNC within a multidisciplinary care team. The findings demonstrated the feasibility of assessing cognitive function within a multidisciplinary team, as well as the associations between domains of cognitive impairment and areas of QoL in patients with HNC. It further demonstrated important associations between cognitive impairment, QoL, and psychosocial variables. The results argue for the incorporation of cognitive screening and assessment of QoL as part of pretreatment assessment for patients, as well as further research into more direct, causal relationships via longitudinal, prospective studies.
